Stelazine

Țară: Noua Zeelandă

Limbă: engleză

Sursă: Medsafe (Medicines Safety Authority)

Ingredient activ:

Trifluoperazine hydrochloride 5.9mg equivalent to 5 mg trifluoperazine;  

Disponibil de la:

Boucher & Muir (NZ) Ltd t/a Mercury Pharma (NZ)

INN (nume internaţional):

Trifluoperazine hydrochloride 5.9 mg (equivalent to 5 mg trifluoperazine)

Dozare:

5 mg

Forma farmaceutică:

Film coated tablet

Compoziție:

Active: Trifluoperazine hydrochloride 5.9mg equivalent to 5 mg trifluoperazine   Excipient: Calcium sulfate dihydrate Gelatin Maize starch Opadry blue OY-4492 Purified talc Purified water as solvent Stearic acid Sucrose

Unități în pachet:

Blister pack, 50 tablets

Clasă:

Prescription

Tip de prescriptie medicala:

Prescription

Produs de:

Egis Pharmaceuticals Ltd

Indicații terapeutice:

Chronic therapy In high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. Short-term therapy Treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. In low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. Stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. For nausea and vomiting of various causes.

Rezumat produs:

Package - Contents - Shelf Life: Blister pack, - 50 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PVC/PVDC blister - 100 tablets - 36 weeks from date of manufacture stored at or below 30°C

Data de autorizare:

1969-12-31

Prospect

Stelazine (trifluoperazine hydrochloride) 

Page 1 of 10 
CONSUMER MEDICINE INFORMATION 

STELAZINE
®

_TRIFLUOPERAZINE HYDROCHLORIDE _
_ _
Film-coated tablets 1 mg, 2 mg and 5 mg 
WHAT IS IN THIS LEAFLET 
Please read this leaflet carefully before you
start taking Stelazine. 

This leaflet answers some
common questions about Stelazine. It does not contain
all the 
available information.  

Reading this leaflet does not take the place of talking to
your doctor or pharmacist.  

All medicines have risks and
benefits. Your doctor has weighed the risks of you taking 
Stelazine against the benefits this medicine is expected
to have for you.  

IF YOU HAVE ANY CONCERNS
ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST.  

KEEP THIS LEAFLET WITH THE MEDICINE.  
You may want to read it again. 
WHAT STELAZINE IS USED FOR 
Stelazine  contains trifluoperazine  hydrochloride  as the
active ingredient. It  belongs to a 
group of medicines called phenothiazine
neuroleptics. It helps to correct chemical 
imbalances in the brain, which may cause mental illness. These
chemicals may also affect 
the parts of the brain which control nausea and vomiting. 

Stelazine is used to treat mental illnesses with
disturbances in thinking, feelings and 
behaviour. It may also be used to treat nausea and
vomiting, or used short term in patients 
with severe anxiety, tension and agitation. 

Your doctor may have
prescribed this medicine for another reason. 
ASK YOUR DOCTOR IF YOU HAVE QUESTIONS ABOUT WHY IT HAS
BEEN PRESCRIBED FOR YOU. 

Stelazine is available only with a doctor's prescription. 

Stelazine is not addictive. 

Stelazine (trifluoperazine hydrochloride) 

Page 2 of 10 
BEFORE YOU TAKE STELAZINE 
Stelazine is not suitable for everyone.  

_WHEN YOU MUST NOT TAKE IT _
 

Caracteristicilor produsului

NEW ZEALAND

DATA SHEET 
STELAZINE
®

_Trifluoperazine dihydrochloride  _
Tablets 1 mg, 2 mg and 5 mg  
Forte Liquid 1 mg/mL _(not available) _
Spansule 15 mg _(not available) _
PRESENTATIONS  
Tablets 1 mg, blue, film-coated, biconvex tablets.  
Tablets 2 mg, blue, film-coated, biconvex tablets. 
Tablets 5 mg, blue, film-coated, biconvex tablets.  
Forte Liquid, oral solution 1 mg/mL, clear, viscous liquid
with a bitter orange taste.  
Spansule, modified release capsules 15 mg, size no. 1 hard gelatin
capsule with opaque yellow 
cap and transparent colourless body containing a mixture
of dark blue, light blue and white 
spherical pellets. Both body and
cap are printed “15” in black. 
INDICATIONS  
CHRONIC THERAPY  
In high doses for management of manifestations of
psychotic disorders, such as acute and chronic 
catatonic hebephrenic and paranoid schizophrenia, psychosis due to
organic brain damage, toxic 
psychosis, manic depressive psychosis, senile psychosis
and mental deficiency.  
SHORT-TERM THERAPY  
Treatment of acute alcoholism for the relief of delusions,
hallucinations and confused state, and for 
the control of accompanying tremulousness
and aggressive behaviour.  

In low doses to control excessive anxiety, tension and
agitation as seen in neuroses or associated 
with somatic conditions. For
nausea and vomiting of various causes.  
DOSAGE AND ADMINISTRATION  
Dosage should be tailored to the individual response, carefully
monitored and adjusted 
accordingly. Because of the inherent long action of the
drug, patients may be controlled on 
convenient twice daily administration.  
FOR OFFICE PATIENTS AND OUTPATIENTS  
Oral - adults:  
Usual dosage is 1 or 2 mg twice a day. If necessary, dosage
may be increased to 6 mg a day, but 
above this level extrapyramidal symptoms are more likely
to occur in some patients.  
Oral –�